Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

Journal of Clinical Oncology

Volumn 31, Issue 8, 2013, Pages 1070-1080

  Ohashi, Kadoaki ^a   Maruvka, Yosef E ^b   Michor, Franziska ^b   Pao, William ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; AP 26113; CANERTINIB; CO 1686; CONMANA; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; MUBRITINIB; NERATINIB; PELITINIB; PLACEBO; TOMTOVOK; UNCLASSIFIED DRUG; VANDETANIB; WZ 4002; XL 647;

CANCER SURVIVAL; CLINICAL FEATURE; DRUG SENSITIVITY; EXON; FATALITY; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHRONIC DISEASE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84875950992     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.3912     Document Type: Review

References (114)

1. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
2. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
3. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004 (Pubitemid 39209661)
4. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
5. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967, 2009
6. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
7. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
8. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742, 2011
9. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
10. Hynes NE, Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5:341-354, 2005 (Pubitemid 40637826)
11. Pao W, Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760-774, 2010
12. Oxnard GR, Arcila ME, Chmielecki J, et al: New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 17:5530-5537, 2011
13. Schlessinger J: Ligand-induced, receptormediated dimerization and activation of EGF receptor. Cell 110:669-672, 2002 (Pubitemid 35283957)
14. Horn L, Chen H, Lovly CM, et al: DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment-A catalogue of clinically relevant somatic mutations in lung cancer. J Clin Oncol 29:494s, 2011 (suppl; abstr 7575
15. Greulich H, Chen TH, Feng W, et al: Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2:e313, 2005
16. Politi K, Zakowski MF, Fan PD, et al: Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20:1496-1510, 2006 (Pubitemid 43830656)
17. Yun CH, Boggon TJ, Li Y, et al: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227, 2007 (Pubitemid 46349842)
18. Yun CH, Mengwasser KE, Toms AV, et al: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105:2070-2075, 2008 (Pubitemid 351439466)
19. He M, Capelletti M, Nafa K, et al: EGFR exon 19 insertions: A new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res 18:1790-1797, 2012
20. Wu JY, Yu CJ, Chang YC, et al: Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 17:3812-3821, 2011
21. Beau-Faller M, Prim N, Ruppert AM, et al: Rare epidermal growth factor receptor (EGFR) mutations in 10,117 patients with non-small cell lung cancer (NSCLC) evaluated by the French ERMETIC IFCT network: Clinical, molecular, and survival data. J Clin Oncol 30:657s, 2012 (suppl; abstr 10507)
22. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005 (Pubitemid 40425952)
23. Bell DW, Lynch TJ, Haserlat SM, et al: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081-8092, 2005 (Pubitemid 46657411)
24. Sun S, Schiller JH, Gazdar AF: Lung cancer in never smokers: A different disease. Nat Rev Cancer 7:778-790, 2007 (Pubitemid 47463669)
25. Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64:8919-8923, 2004 (Pubitemid 39665498)
26. Sun Y, Ren Y, Fang Z, et al: Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28:4616-4620, 2010
27. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005 (Pubitemid 41540110)
28. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
29. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008
30. Fukuoka M, Wu YL, Thongprasert S, et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866-2874, 2011
31. Mitsudomi T, Morita S, Yatabe Y: Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol 30:485s, 2012 (suppl; abstr 7521)
32. Zhou C, Wu YL, Liu X: Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol 30:485s, 2012 (suppl; abstr 7520)
33. Nguyen KS, Kobayashi S, Costa DB: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10:281-289, 2009
34. Garassino MC, Martelli O, Bettini A, et al: TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol 30:480s, 2012 (suppl; abstr LBA7501)
35. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
36. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
37. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
38. Janne PA, Wang X, Socinski MA, et al: Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 30:2063-2069, 2012
39. Kubota K, Watanabe K, Kunitoh H, et al: Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254-261, 2004 (Pubitemid 41095089)
40. Ohe Y, Ohashi Y, Kubota K, et al: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-arm cooperative study in Japan. Ann Oncol 18:317-323, 2007 (Pubitemid 46323100)
41. Takano T, Fukui T, Ohe Y, et al: EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: A historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 26: 5589-5595, 2008
42. Woodcock J: AstraZeneca Pharmaceuticals LP: Withdrawal of approval of a new drug Application for IRESSA. Federal Register 77:24723-24724, 2012
43. Cokkinides V, Bandi P, McMahon C, et al: Tobacco control in the United States: Recent progress and opportunities. CA Cancer J Clin 59:352-365, 2009
44. Huang X, Cortes J, Kantarjian H: Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118:3123-3127, 2012
45. Kantarjian H, O'Brien S, Jabbour E, et al: Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience. Blood 119:1981-1987, 2012
46. Yasuda H, Kobayashi S, Costa DB: EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications. Lancet Oncol 13:e23-e31, 2012
47. Girard N, Lou E, Azzoli CG, et al: Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: A preliminary report. Clin Cancer Res 16:755-763, 2010
48. Bell DW, Gore I, Okimoto RA, et al: Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37:1315-1316, 2005 (Pubitemid 41722184)
49. Oxnard GR, Miller VA, Robson ME, et al: Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol 7:1049-1052, 2012
50. Inukai M, Toyooka S, Ito S, et al: Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66:7854-7858, 2006 (Pubitemid 44299146)
51. Chmielecki J, Foo J, Oxnard GR, et al: Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3:90ra59, 2011
52. Maheswaran S, Sequist LV, Nagrath S, et al: Detection of mutations in EGFR in circulating lungcancer cells. N Engl J Med 359:366-377, 2008
53. Rosell R, Molina MA, Costa C, et al: Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-smallcell lung cancer patients with EGFR mutations. Clin Cancer Res 17:1160-1168, 2011
54. Su KY, Chen HY, Li KC, et al: Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30:433-440, 2012
55. Mir O, Blanchet B, Goldwasser F: Druginduced effects on erlotinib metabolism. N Engl J Med 365:379-380, 2011
56. Hamilton M, Wolf JL, Rusk J, et al: Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 12:2166-2171, 2006
57. Garcia-Donas J, Esteban E, Leandro-García LJ, et al: Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study. Lancet Oncol 12:1143-1150, 2011
58. Gong Y, Somwar R, Politi K, et al: Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 4:e294, 2007
59. Faber AC, Corcoran RB, Ebi H, et al: BIM expression in treatment naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 1:352-365, 2011
60. Ng KP, Hillmer AM, Chuah CT, et al: A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18:521-528, 2012
61. Pao W, Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175-180, 2011
62. Bergethon K, Shaw AT, Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870, 2012
63. Pao W, Hutchinson KE: Chipping away at the lung cancer genome. Nat Med 18:349-351, 2012
64. Yamamoto H, Shigematsu H, Nomura M, et al: PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68:6913-6921, 2008
65. Engelman JA, Mukohara T, Zejnullahu K, et al: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 116:2695-2706, 2006 (Pubitemid 44511633)
66. Bivona TG, Hieronymus H, Parker J, et al: FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471:523-526, 2011
67. Yano S, Yamada T, Takeuchi S, et al: Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6:2011-2017, 2011
68. Yao Z, Fenoglio S, Gao DC, et al: TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 107:15535-15540, 2010
69. Arcila ME, Oxnard GR, Nafa K, et al: Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acidbased assay. Clin Cancer Res 17:1169-1180, 2011
70. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26, 2011
71. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005 (Pubitemid 40271173)
72. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73, 2005
73. Omuro AM, Kris MG, Miller VA, et al: High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103: 2344-2348, 2005 (Pubitemid 40686581)
74. Heon S, Yeap BY, Britt GJ, et al: Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 16:5873-5882, 2010
75. Jackman DM, Holmes AJ, Lindeman N, et al: Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24: 4517-4520, 2006 (Pubitemid 46630993)
76. Katayama T, Shimizu J, Suda K, et al: Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4:1415-1419, 2009
77. Clarke JL, Pao W, Wu N, et al: High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99:283-286, 2010
78. Grommes C, Oxnard GR, Kris MG, et al: "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 13:1364-1369, 2011
79. Hata A, Ktakami N, Yoshioka H, et al: Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: Comparison between T790M mutation-positive and-negative populations. J Clin Oncol 30:487s, 2012 (suppl; abstr 7528)
80. Togashi Y, Masago K, Fukudo M, et al: Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol 68:1089-1092, 2011
81. Milton DT, Azzoli CG, Heelan RT, et al: A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 107:1034-1041, 2006 (Pubitemid 44291152)
82. Picard S, Titier K, Etienne G, et al: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose imatinib in chronic myeloid leukemia. Blood 109:3496-3499, 2007 (Pubitemid 46572540)
83. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007 (Pubitemid 46799492)
84. Bean J, Brennan C, Shih JY, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932-20937, 2007
85. Yano S, Wang W, Li Q, et al: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68:9479-9487, 2008
86. Turke AB, Zejnullahu K, Wu YL, et al: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17:77-88, 2010
87. Ohashi K, Sequist LV, Arcila ME, et al: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 109:E2127-E2133, 2012
88. Takezawa K, Pirazzoli V, Arcila ME, et al: HER2 amplification: A potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2:922-933, 2012
89. Cheung HW, Du J, Boehm JS, et al: Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 1:608-625, 2011
90. Ercan D, Xu C, Yanagita M, et al: Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2:934-947, 2012
91. Zakowski MF, Ladanyi M, Kris MG: EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355:213-215, 2006 (Pubitemid 44050422)
92. Zhang Z, Lee JC, Lin L, et al: Activation of the AXL kinase causes resistance to EGFRtargeted therapy in lung cancer. Nat Genet 44: 852-860, 2012
93. Meuwissen R, Linn SC, Linnoila RI, et al: Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4:181-189, 2003 (Pubitemid 37163832)
94. Suda K, Tomizawa K, Fujii M, et al: Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6:1152-1161, 2011
95. Chang TH, Tsai MF, Su KY, et al: Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med 183:1071-1079, 2011
96. Lee JS, Hirsh V, Park K, et al: Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 30:1114-1121, 2012
97. Natale RB, Thongprasert S, Greco FA, et al: Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29:1059-1066, 2011
98. Herbst RS, Sun Y, Eberhardt WE, et al: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol 11:619-626, 2010
99. Ercan D, Zejnullahu K, Yonesaka K, et al: Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29:2346-2356, 2010
100. Yang JCH, Schuler MH, Yamamoto N, et al: LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 30:480s, 2012 (suppl; abstr LBA7500)
101. Miller VA, Hirsh V, Cadranel J, et al: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol 13:528-538, 2012
102. Kris MG, Mok T, Ou SHI, et al: First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFRmutant lung cancers. J Clin Oncol 30:487s, 2012 (suppl; abstr 7530)
103. Zhou W, Ercan D, Chen L, et al: Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070-1074, 2009
104. Walter AO, Tjin R, Haringsma H, et al: CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations. Mol Cancer Ther 10, 2011 (suppl 1; abstr C189)
105. Rivera VM, Wang F, Anjum R, et al: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC. Cancer Res 72, 2012 (suppl 1; abstr 1794)
106. Janjigian YY, Groen HJ, Horn L, et al: Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 29:486s, 2011 (suppl; abstr 7525)
107. Watanabe S, Tanaka J, Ota T, et al: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: A retrospective analysis. BMC Cancer 11:1, 2011
108. Oxnard GR, Arcila ME, Sima CS, et al: Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17:1616-1622, 2011
109. Rosell R, Molina-Vila MA, Taron M, et al: EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study. J Clin Oncol 30:485s, 2012 (suppl; Abstr 7522)
110. Riely GJ, Kris MG, Zhao B, et al: Prospective assessment of discontinuation and reinitiationof erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150-5155, 2007 (Pubitemid 47502083)
111. Faehling M, Eckert R, Kamp TG, et al: Treatment with EGFR tyrosine kinase inhibitors beyond progression in long-term responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival. J Clin Oncol 30:497s, 2012 (suppl; abstr 7572)
112. Goldberg SB, Oxnard GR, Digumarthy S, et al: Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI). J Clin Oncol 30:486s, 2012 (suppl; abstr 7524)
113. Oxnard GR, Lo P, Jackman DM, et al: Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer. J Clin Oncol 30:491s, 2012 (suppl; abstr 7547)
114. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012